OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO) announced that the ClinicalTrials.gov public website (ClinicalTrials.gov Identifier: NCT05759208) now includes information about its trial that assesses the safety and effectiveness of OK-101 in individuals with dry eye disease (DED).
The company is currently activating clinical sites for the trial and preparing the clinical trial drug product OK-101 for shipment to those sites. The first-patient first-visit initiation of the trial is expected in the second quarter of 2023, with top-line data anticipated in the fourth quarter.
OKYO CEO Gary Jacob expressed enthusiasm about the drug’s potential to provide an alternative treatment option for DED patients currently underserved by approved drugs. In addition, the company has raised approximately US$5.6mln gross in a private placing of ADS and ordinary shares in the US.
About OK-101
OK-101 is a lipid conjugated chemerin peptide antagonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide (MAP) technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain; and is designed to combat washout through the inclusion of the lipid ‘anchor’ contained in the candidate drug molecule to enhance the residence time of OK-101 within the ocular environment.
